Related Experiment Video
Updated: Mar 3, 2026
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
Ten-color 15-antibody flow cytometry panel for immunophenotyping of lymphocyte population
Insights
A new lymphoproliferative disorder screening tube (LPD-ST) offers comprehensive immunophenotyping, reducing the need for additional tests. This validated method improves efficiency and lowers costs for diagnosing blood cancers.
Area of Science:
- Hematology
- Immunology
- Clinical Pathology
Background:
- Lymphoproliferative disorders (LPDs) require accurate immunophenotyping for diagnosis.
- Existing lymphocyte subset panels can be labor-intensive and time-consuming.
- There is a need for efficient and cost-effective screening methods for LPDs.
Purpose of the Study:
- To develop and validate a novel lymphoproliferative disorder screening tube (LPD-ST).
- To assess the LPD-ST's ability to minimize the need for additional immunophenotyping tests.
- To evaluate the LPD-ST's suitability for routine clinical practice and paucicellular samples.
Main Methods:
- Development of the LPD-ST panel including specific antibody conjugates (e.g., CD4/kappa FITC, CD8/lambda PE).
- Validation of the LPD-ST against established lymphocyte subset panels in Canada and Sweden.
- Clinical implementation of the LPD-ST using dried monoclonal antibody reagents on a large patient cohort.
Main Results:
- The LPD-ST significantly reduced the need for additional testing for B-cell populations (31% found, 52% diagnosed) and T-cell populations (3% confirmed aberrant).
- 12% of normal/reactive samples required further testing, primarily due to abnormal CD4/CD8 ratios.
- The LPD-ST demonstrated suitability for paucicellular samples like cerebrospinal fluid.
Conclusions:
- The LPD-ST provides comprehensive immunophenotyping, minimizing repeat testing for lymphoproliferative disorders.
- This screening tube improves turn-around time and reduces costs associated with LPD diagnosis.
- The LPD-ST is a valuable tool for routine clinical practice, including challenging sample types.
Abstract:
We have developed a lymphoproliferative disorder screening tube (LPD-ST) with the aim to provide comprehensive immunophenotyping of lymphocyte subsets with minimal need for additional testing. The LPD-ST consists of CD4/kappa FITC, CD8/lambda PE, CD3/CD14ECD, CD38PC5.5, CD20/CD56PC7, CD10APC, CD19APC-A700, CD5APC-A750, CD57/CD23PB and CD45KO. The LPD-ST was validated against previously used lymphocyte subset panels in Canada (n=60) and in Sweden (n=43) and against the OneFlow™ LST (n=60). The LPD-ST panel was then implemented in clinical practice using dried monoclonal antibody reagents (Duraclone® ) on 649 patient samples in Sweden. In 204 of 649 samples (31%), a monotypic B-cell population was found. Of these cases, a final diagnosis could be rendered in 106 cases (52%), and in the remainder, additional B-cell immunophenotyping was performed. In 20 (3%) samples, an aberrant T-cell population was confirmed by additional testing. Of 425 samples diagnosed as normal/reactive lymphoid tissue, 50 (12%) required additional immunophenotyping, mostly due to an abnormal CD4/CD8 ratio. The LPD-ST tube significantly minimizes the need for additional testing, improves the turn-around time, and reduces the cost of LPD immunophenotyping. It is also suitable for investigating paucicellular samples such as cerebrospinal fluid or fine needle aspirates.
